ImmuPharma (IMM.L) Stock Price
£4 11.3%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
2 -
Technical
7
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on ImmuPharma, AI stock picks, stock alerts and much more.
IMM.L AI Stock Analysis
AI stock analysis for IMM.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like ImmuPharma (IMM.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
ImmuPharma (IMM.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of ImmuPharma (IMM.L), currently trading at £4, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About IMM.L
-
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics.
-
Symbol
IMM.L
-
Market
LSE
-
Industry
Biotechnology
-
Market Cap
18.1M
Similar Stocks
 |
Codexis 0I0X.L |
$4.37 1.4% |
3 |
 |
Oxford Nanopore Technologies plc ONT.L |
£135.5 1.1% |
5 |
 |
Sareum Holdings SAR.L |
£19.8 2.9% |
3 |
 |
Viridian Therapeutics 0K1R.L |
$18.7 2.3% |
6 |
 |
Avacta Group Plc AVCT.L |
£46.75 1.6% |
4 |
News
IMM.L Alternative Data
Web Traffic
ImmuPharma receives an estimated 1336 monthly visitors to immupharma.co.uk.
-
Web Traffic
1336
-
Change from Previous Month
34.5%
-
3 Month Change
7.3%
News Mentions
ImmuPharma was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Twitter Followers
ImmuPharma has 642 Twitter Followers on its main Twitter (also known as X) account, which is up by 3% over the last month.
-
Twitter Followers
642
-
Daily Change
0%
-
1 Month Change
3%
-
3 Month Change
0.6%
LinkedIn Followers
618 are following ImmuPharma on LinkedIn, up by 3.7% over the last month.
-
LinkedIn Followers
618
-
Daily Change
0.2%
-
1 Month Change
3.7%
-
3 Month Change
6.4%
Job Postings
ImmuPharma currenly has an estimated 0 open job postings.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Employees
According to LinkedIn, ImmuPharma has 2 employees.
-
LinkedIn Employees
2
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
IMM.L Financials
IMM.L Key Metrics
-
Total Revenue
£0
-
Net Income
-£193.9K
-
Earnings per Share
-£0.0005
-
Free cash flow
-£438.4K
-
EBITDA
-£372.7K
-
EBITDA Ratio
0
-
Total Assets
£4.1M
IMM.L 2-year Revenue & Income
IMM.L 2-year Free Cash Flow
IMM.L Technicals
IMM.L SMA
IMM.L RSI
FAQ
What's the current price of ImmuPharma (IMM.L) Stock?
The price of an ImmuPharma (IMM.L) share is £4.
What's the market cap of ImmuPharma?
The current market cap of ImmuPharma is 18.1M.
Should I buy or sell IMM.L?
ImmuPharma shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, ImmuPharma is better viewed as a hold or accumulate position while waiting for further developments.
Is ImmuPharma a good investment?
The current analysis of ImmuPharma's fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in ImmuPharma's portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy ImmuPharma (IMM.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for ImmuPharma stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to ImmuPharma (IMM.L) that investors often compare it to?
ImmuPharma (IMM.L) is often compared to similar stocks such as Codexis, Oxford Nanopore Technologies plc, Sareum Holdings, Viridian Therapeutics and Avacta Group Plc.
What is the forecast for ImmuPharma's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast ImmuPharma's stock price to be around £5.12 in 2026. Starting from the current price of £4, this represents a 27.9% change in price, indicating a bullish outlook for the stock.
How to buy ImmuPharma (IMM.L) Stock?
ImmuPharma stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy ImmuPharma shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.